Aurinia Pharmaceuticals
Victoria
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and Dry Eye Syndrome.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $100K – $500K
- Total funding: $658.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2020)
- Ticker: nasdaq:AUPH
- Website: auriniapharma.com
- Phone: +1 (250) 744-2487
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/aurinia-pharmaceuticals-78195 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.